CAS 27262

Basic Info.

Model NO.	27262-47-1
Storage Temp	+25ºC
Quality Requirement	Strictly Quality Control
Transport Package	25kg/Drum/1000g/Bag/10g/Bag
Specification	100% raw material
Trademark	Widely
Origin	China
Production Capacity	1000kg/Mon

Product Description

Chemical Properties	White Solid
Originator	Chirocaine,Abbott Laboratories
Uses	Local anaesthetic used for epidural and intrathecal anaesthesia.
Manufacturing Process	Synthesis of L-pipecolic acid 2,6-xylidide (Patent US 4,695,576)130 g of pipecolic acid and 158.6 g of Laevo (+)-tartaric acid are dissolved under stirring in 2 L 95% ethyl alcohol and 125 ml water at 80°C. The solution is allowed to cool to room temperature and after two days the crystallized D-pipecolic-tartrate is separated. The L-pipecolic-tartrate remains in solution. The filtrate is evaporated and dissolved in 5% acetic acid. Finally the solution is treated with Amberlite IR 45* in an ion exchanger. The eluate thus obtained is evaporated and the resulting crystalline residue is dried with potassium hydroxide in vacuo. The product obtained consists of L-pipecolic acid [α]D24 = -26.2°(C = 5, H2O).4 g of phosphorus pentachloride was added to a suspension of 4 g of Lpipecolic acid hydrochloride in 40 ml acetylchloride. The initial reaction is effected at a temperature of about 35°C under stirring for 2 hours. The chlorination is completed by adding during a time period of about 10 minutes an additional two grams of phosphorus pentachloride and stirring over a further period of 4 hours while maintaining the suspension at a temperature of about 35°C. The resulting L-pipecolic acid chloride hydrochloride is filtered and washed with toluene and acetone. The crystalline residue is then dried in vacuo, m.p. 155°C.A mixture of 2.7 ml 2,6-dimethylaniline, 4 ml acetone, and 4 ml Nmethylpyrrolidone is gradually added under stirring for 2 hours at 70°C to a suspension of 4 g of L-pipecolic acid chloride hydrochloride. This yields a crystalline product, which is filtered, washed with acetone and dried. This crystalline product is then dissolved in water and the base is precipitated by the addition of ammonia. The base is then extracted by the use of toluene and is recovered by evaporation. The base is recrystallized from a mixture of hexane and ethanol to yield L-pipecolic acid 2,6-xylidide. The melting point of this compound is 129-130°C.Preparation of L-N-n-butylpipecilic acid 2,6-xylidide may de carried out by analogy with the preparation of L-N-n-propylpipecolic acid 2,6-xylidide (Patent US 5,777,124).n-Butylbromide and potassium carbonate are added to a solution of L-pipecolic acid 2,6-xylidide dissolved in isopropyl alcohol. Thereafter, 5 ml of water is added to the mixture and the reaction is carried out for 4 hours at 72°C.To complete the reaction, a further 0.8 ml n-butylbromide are added under continuous stirring and heating for 4 hours. The residue is treated with a mixture of 250 ml toluene and an equal amount of water at 50°C. The toluene layer is separated and washed three times with 100 ml warm water (40°C). A 175 ml portion of the toluene is removed by evaporation and the remainder is stored at +5°C for 6 hours to achieve crude crystalline L-N-n-butylpipecilic acid 2,6-xylidide. The crystalline product is separated by filtration, washed with some cooled toluene and dried at 70°C. Recrystallization may be carried from toluene. This product is dissolved in 100 ml ethanol and neutralized with concentrated hydrochloric acid. Ethanol is removed by evaporation and the hydrochloride product obtained is vacuum dried. Finally the latter is recrystallized from isopropyl alcohol.
Therapeutic Function	Local anesthetic
General Description	Levobupivacaine is the pure "S" enantiomer of bupivacaineand in vivo and in vitro studies confirm that it does notundergo metabolic inversion to R(+) bupivacaine. The pKaof the tertiary nitrogen is 8.09, the same as bupivacaine's pKa. Levobupivacaine is available in solution for epiduraladministration, peripheral nerve block administration, andinfiltration anesthesia. Clinical trials have shown thatlevobupivacaine and bupivacaine have similar anestheticeffects. Levobupivacaine has lower CNS and cardiotoxicitythan bupivacaine although unintended intravenousinjection when performing nerve blocks may result intoxicity. Racemic bupivacaine is metabolized extensivelywith no unchanged drug found in the urine or feces. Liverenzymes including the CYP3A4 and CYP1A2 isoforms areresponsible for N-dealkylation and 3-hydroxylation oflevobupivacaine followed by glucuronidation or sulfation.
Pharmacology	This is the laevo (S-) enantiomer of bupivacaine, with similar properties to the racemic mixture, though it has slightly higher protein binding and clearance and hence a lower potential for cardiac and CNS toxicity. In practice, several other factors contribute to local anaesthetic toxicity, and the recommended maximum doses remain the same. Its formulation is expressed as percentage weight per unit volume of free base; racemic bupivacaine is expressed as percentage weight per unit volume of hydrochloride salt. Levobupivacaine therefore contains 13% more active molecules for a given dose.

Hubei weideli Chemical Reagent Co., Ltd., located in Wuhan East Lake New Technology Development Zone, is a manufacturing supplier focusing on reagent products for scientific research, and its business scope includes the manufacturing of special chemical products; Disinfectant production; Sales of special chemical products; Disinfectant sales; Research and development of biological feed; Research and development of bio based materials technology; Research and development of biochemical products technology; Technical services, technical development, technical consultation, technical exchange, technology transfer and technology promotion; Sales of instruments and meters; Sales of daily glass products; Sales of technical glass products; Sales of electronic special materials; Technology import and export; Import and export of goods; Veterinary drug management; Production of disinfection products for the prevention and treatment of infectious diseases.The company has gradually established extensive cooperation with scientific research institutions in Colleges and universities and powerful enterprises to lay a solid foundation for technological production; At the same time, we will recruit talents all over the country and keep them fresh and energetic; With more than ten years of experience and accumulation in the industry, the company further improves its market competitiveness and strengthens its support to customers.With the help of modern ERP system, the company provides customers with accurate quotation and inventory information in time. It has a warehouse base and Laboratory of more than 1000 square meters in Jiangxia District, Wuhan. The system inventory products can be ordered on the same day, and the order number is given on the same day of delivery. The information can be queried online, followed up in real time, and customer service provides after-sales support services.Hubei weideli Chemical Reagent Co., Ltd. is committed to scientific research.

I. Do you always have this products in stock?Our company has more than 1000 kinds of products in stock. We usually have them in stock. We can show you the information, forms or pictures of our warehouse at any time. If the stock is insufficient, our company will replenish them as soon as possible according to the ERP system.2. What certificates and documents do you offer?According to the situation of products, we can provide COA, NMR, LC, MS, synthesis process, MQA, MSDS, etc3. Why should I choose you?Stock in stock and deliver in timeReasonable priceProduct technology and data supportProfessional sales teamPerfect pre-sale and after-sale service4. Can I get best price from you?We don* t pursue expensive profitsWe always try to give best offerYou can also enjoy fun of bargaining5. How should I pay?T/T bank transfer West union PayPal